Supernus Pharmaceuticals Target of Unusually Large Options Trading (SUPN)

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) was the target of some unusual options trading on Wednesday. Stock investors bought 906 call options on the company. This is an increase of approximately 1,712% compared to the average volume of 50 call options.

In other news, VP Padmanabh P. Bhatt sold 20,000 shares of the stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $44.98, for a total transaction of $899,600.00. Following the transaction, the vice president now owns 32,500 shares of the company’s stock, valued at approximately $1,461,850. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Gregory S. Patrick sold 50,000 shares of the stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $43.56, for a total value of $2,178,000.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 145,750 shares of company stock worth $6,173,173. 6.70% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Supernus Pharmaceuticals by 278.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock valued at $130,000 after buying an additional 2,220 shares during the last quarter. Riverhead Capital Management LLC grew its holdings in Supernus Pharmaceuticals by 91.4% in the 2nd quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 1,462 shares during the last quarter. Advisor Group Inc. grew its holdings in Supernus Pharmaceuticals by 13.7% in the 2nd quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock valued at $145,000 after buying an additional 410 shares during the last quarter. Victory Capital Management Inc. grew its holdings in Supernus Pharmaceuticals by 17.7% in the 2nd quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock valued at $148,000 after buying an additional 517 shares during the last quarter. Finally, Flinton Capital Management LLC grew its holdings in Supernus Pharmaceuticals by 88.9% in the 2nd quarter. Flinton Capital Management LLC now owns 4,760 shares of the specialty pharmaceutical company’s stock valued at $205,000 after buying an additional 2,240 shares during the last quarter. 98.22% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Supernus Pharmaceuticals (SUPN) opened at $46.90 on Friday. The stock has a market capitalization of $2,400.00, a P/E ratio of 42.64 and a beta of 1.17. Supernus Pharmaceuticals has a fifty-two week low of $23.10 and a fifty-two week high of $50.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.02. The firm had revenue of $80.40 million for the quarter, compared to analyst estimates of $78.74 million. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The business’s revenue for the quarter was up 41.5% compared to the same quarter last year. equities research analysts predict that Supernus Pharmaceuticals will post 1.07 earnings per share for the current year.

A number of brokerages have recently commented on SUPN. B. Riley reissued a “buy” rating and set a $54.00 price objective on shares of Supernus Pharmaceuticals in a report on Thursday. Zacks Investment Research lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 12th. BidaskClub raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 11th. Janney Montgomery Scott raised Supernus Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $47.00 price objective on the stock in a report on Monday, December 4th. Finally, ValuEngine lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Three research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $49.90.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/01/20/supernus-pharmaceuticals-target-of-unusually-large-options-trading-supn.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit